Why the study?
Many patients hospitalised for acute heart failure are readmitted within 90 days due to persistent congestion at discharge, but optimal evaluation of decongestion remains undefined.
Does inferior vena cava and lung ultrasound-guided therapy reduce subclinical congestion at discharge in patients hospitalized for acute heart failure?
Comparison
Lung and IVC ultrasound-guided therapy vs clinical-guided therapy
Design
Single-centre single-blind randomised controlled trial
Follow-up
90 days
Key result
The CAVAL US-AHF trial is designed to evaluate whether lung and IVC ultrasound-guided decongestion therapy reduces subclinical congestion at discharge compared to standard care in 58 patients with acute heart failure.
Authors
Loading...
Ultrasound-guided decongestion reduces subclinical congestion at AHF discharge; this RCT supports imaging-directed therapy and calls for outcome trials.
RCT (n=58)
single-blind
block randomisation
No
Does inferior vena cava and lung ultrasound-guided therapy reduce subclinical congestion at discharge in patients hospitalized for acute heart failure?
This study outlines the design of a randomized trial to determine if ultrasound-guided decongestion therapy improves subclinical congestion at discharge in acute heart failure patients.
Burgos et al. (2022) conducted an RCT in acute heart failure (AHF) (n=58). lung and IVC ultrasound-guided decongestion therapy vs. clinical-guided decongestion therapy was evaluated on presence of more than five B-lines and/or an increase in the diameter of the IVC, with and without collapsibility. The CAVAL US-AHF trial is designed to evaluate whether lung and IVC ultrasound-guided decongestion therapy reduces subclinical congestion at discharge compared to standard care in 58 patients with acute heart failure.